Watchlist
ATRC · AtriCure, Inc.
Last analysed ·
Against its published line
Nothing is through its line on this close.
How to read this
The red mark is the published kill line — the price that would prove the pick wrong. The dot is where the name closed on 18 September 2026; a dot LEFT of the mark has closed through its line.
Distance is drawn on a square-root scale, so close calls get the room. Past 8% a row stops competing and reads well clear, with a hollow dot to say the figure is off the drawn scale. Rows run tightest first.
Current thesis
AtriCure’s profitability and clinical-expansion story now has to sustain its re-rating after September 21 index inclusion. A weekly close at or above Needham’s $64 target would complete the price case; a weekly close below $47 would invalidate it.
Kill line
A weekly close below $47 invalidates the September announcement leg. Separately, a reduction in fiscal 2026 revenue guidance below the $602 million lower bound issued on 2026-07-23 would break the operating rationale.
Pick status
Open commitment catalyst in 1dscored if the kill line above fires How this is scored →Latest analysis and events for ATRC —
As of 19 September 2026, the latest FrontierPicks analysis for AtriCure, Inc. (ATRC): AtriCure’s profitability and clinical-expansion story now has to sustain its re-rating after September 21 index inclusion. A weekly close at or above Needham’s $64 target would complete the price case; a weekly close below $47 would invalidate it.
Kill line: A weekly close below $47 invalidates the September announcement leg. Separately, a reduction in fiscal 2026 revenue guidance below the $602 million lower bound issued on 2026-07-23 would break the operating rationale.
Next dated event on file: — catalyst in 1d.
Current Thesis
AtriCure’s profitability and clinical-expansion story now has to sustain its re-rating after September 21 index inclusion; a weekly close at or above Needham’s $64 target completes the price case, while a weekly close below $47 invalidates it. Needham published that target on 2026-09-02, and S&P Dow Jones Indices announced inclusion on 2026-09-04, effective before trading on 2026-09-21. Index announcement
The September 6 assessment now has company commentary and another analyst endorsement behind it. At the 2026-09-08 Wells Fargo conference, Chief Financial Officer Angela Wirick described pain management as offsetting pressure in hybrid ablation and international operations. Stifel reiterated its $65 target on 2026-09-17; this was a reiteration, not a newly raised forecast. Company transcript, Stifel coverage
The research inference is that the narrative is maturing — profitability has been public since the 2026-07-23 results, while the latest dated endorsement on 2026-09-17 revisits clinical adoption and competition. The September 18 price record shows continued strength, but neither analyst coverage nor index membership establishes a higher revenue trajectory.
Bullish and bearish views on AtriCure, Inc.
The model's bull view on AtriCure, Inc. (ATRC), in brief: Profitability has reported support. On 2026-07-23, AtriCure reported second-quarter revenue of $153.6 million, up 12.8% year over year, and adjusted earnings per share of $0.18. Its updated fiscal 2026 guidance included adjusted earnings per share of $0.24–$0.32 and revenue of… The bear view: Competitive reassurance has limited breadth. Both cases follow in full.
Bull Case
- Profitability has reported support. On 2026-07-23, AtriCure reported second-quarter revenue of $153.6 million, up 12.8% year over year, and adjusted earnings per share of $0.18. Its updated fiscal 2026 guidance included adjusted earnings per share of $0.24–$0.32 and revenue of $602–610 million.
- Pain growth has operational support. Second-quarter pain-management revenue was $27.1 million, up 27.8% year over year, in the 2026-07-23 disclosure. On 2026-09-08, Wirick attributed most recent growth to volume rather than pricing, strengthening the adoption explanation. Company transcript
- Clinical expansion retains analyst backing. Needham’s 2026-09-02 assessment linked its $64 target to BoxX-NoAF, which tests EnCompass plus AtriClip in cardiac surgery. Its anticipated end-2026 enrolment completion and first-half 2027 initial results remain forecasts; enrolment extending beyond 2026 would invalidate that timetable.
Bear Case
- Competitive reassurance has limited breadth. Stifel’s 2026-09-17 commentary reported that four of six surveyed surgeons strongly preferred AtriCure’s appendage-management technology and did not use competitors. The sample is too small to establish market-wide retention or quantify Edwards’ competitive impact. Stifel coverage
- Management still described uneven demand. On 2026-09-08, Wirick acknowledged continued hybrid-ablation pressure and international execution issues. Her expectation of only modest Edwards-related disruption in 2026 is management’s assessment, not measured market-share evidence. Company transcript
- Index inclusion does not measure demand. The 2026-09-04 announcement establishes a membership change on 2026-09-21. It supplies no fund-flow amount or evidence of how much index-related demand remained after the September 18 close. Index announcement
Setup & Price Structure
The adjusted market record for 2026-09-18 gives a $58.10 close, a $59.12 trailing annual high and a 104.3% three-month price increase. The close was 1.7% below that high, with the 14-day relative strength index (RSI) at 80.5. Those are momentum observations; they do not identify the buyers or establish retail crowding. No moving-average reading or measured index flow is available.
The September 18 close exceeds BTIG’s $55 target dated 2026-08-24, while remaining below Piper Sandler’s $60 target dated 2026-08-27 and Needham’s $64 target dated 2026-09-02. These are analyst valuations, not demonstrated chart support. Dated analyst actions
The published September 6 thesis used $47 as its weekly invalidation threshold, tied to the September announcement leg. That threshold remains the research condition; the available price record does not establish a newer support shelf. Medium conviction reflects reported profitability and continuing analyst support against an unmeasured post-inclusion demand picture.
Catalyst Calendar (next 30 days)
- 2026-09-21 — Index inclusion takes effect. AtriCure joins the S&P SmallCap 600 before the open under the 2026-09-04 announcement. Subsequent closes test whether strength persists after the scheduled membership change; inclusion itself supplies no earnings confirmation. Index announcement
- ~2026-10-28, estimated — Third-quarter results. Beyond the next 30 days, Stock Analysis lists this earnings date, but AtriCure’s event calendar checked on 2026-09-20 provides no upcoming company-confirmed date. This report tests the $602–610 million fiscal 2026 revenue guidance issued on 2026-07-23. Third-party calendar, Company calendar
What Would Change Our Mind
Loss of the September announcement structure ends the price thesis: a weekly close below $47 is the observable failure condition retained from the September 6 assessment. Conversely, a weekly close at or above Needham’s September 2 target of $64 completes the stated price case.
The operating rationale would separately fail if AtriCure reduced its fiscal 2026 revenue outlook below the $602 million lower bound issued on 2026-07-23. Unchanged guidance at the third-quarter report would leave revenue acceleration unconfirmed; it would not, by itself, demonstrate deterioration.
Correlation Notes
FrontierPicks’ Medtech & diagnostics coverage classification moved from maturing on 2026-09-06 to saturated on 2026-09-13. That is an editorial assessment of the group, not a measured return correlation or a verdict on AtriCure. ATRC’s September 18 proximity to its annual high contrasts with that cooling coverage assessment.
No matched peer-return series is available to establish a correlation with HTFL, INSP, PRPO, BFLY or TXG. AtriCure’s 2026-07-23 appendage-management revenue of $51.6 million provides a concrete company exposure to assess; the shared theme tag alone does not establish common earnings drivers.
Notes
- Roughly a third of revenue sits in appendage management ($51.6M of $153.6M in Q2 2026), the franchise contested by Medtronic Penditure and Edwards ECLIPTIS.
- Calendar fiscal year; quarterly results have landed in late January, April, July and October, with Q3 2026 not yet formally dated by the company.
- Revenue is booked in hospital cardiac-surgery suites, so quarterly volumes track elective surgical scheduling and hospital staffing conditions.
- LeAAPS readout timing is management commentary from the 2026-08-11 fireside chat, not a company-issued schedule; the original guide was end-of-decade.
- Officer sales are running under Rule 10b5-1 plans (the CTO's adopted 2026-02-20), so individual trade dates are pre-scheduled rather than discretionary.
Related · shared themes
TXG
10x Genomics, Inc.
10x Genomics' Atera recovery now needs deliveries and revenue confirmation after clearing its earlier price hurdle. Approximately 40 second-half 2026 shipments and full-year revenue of $610–630 million would substantiate the case before a weekly close below $58.57 invalidates the structure.
ITGR
Integer Holdings Corporation
Integer Holdings Corporation’s $127.00 cash acquisition by KKR remains a completion thesis, strengthened by the 2026-09-03 merger proxy. Completion by year-end 2026 would settle the case; a daily close below $118 invalidates it.
PSNL
Personalis, Inc.
The MRD story has been overtaken by a live sale process: StreetInsider reported 2026-07-17 that Personalis retained Centerview, TD Securities and Cooley after takeover interest from Merck (already a >10% holder and 19% of Q1 revenue) plus two other suitors. Price broke to a $16.39 52-week high; Needham $17 and TD Cowen $18 now sit above the tape. Aug-4 Q2 is the next hard date.
VREX
Varex Imaging Corporation
Varex Imaging Corporation’s $18.90 cash acquisition by Teledyne remains a completion thesis. The 2026-09-08 preliminary proxy advances the process; payment resolves the case, while a daily close below $17.50 invalidates it.
See also · stocks to watch